Craig-Hallum initiated coverage on iSpecimen with a new price target
$ISPC
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Craig-Hallum initiated coverage of iSpecimen with a rating of Buy and set a new price target of $20.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/4/2022 | $20.00 | Buy | Craig-Hallum |
| 11/22/2021 | $10.00 → $12.00 | Buy | EF Hutton |
Strengthens iSpecimen's next-generation marketplace platform Woburn, MA, March 12, 2026 (GLOBE NEWSWIRE) -- iSpecimen Inc. (the "Company") (NASDAQ:ISPC), a leading technology marketplace connecting researchers with biospecimen suppliers, today announced the launch of its new AI-powered Inventory Agent, a purpose-built tool designed to help accelerate the process of reviewing incoming biospecimen requests and matching them with available inventory across its global supplier network. The internally developed AI agent analyzes incoming request criteria and is designed to identify potential biospecimen matches, enabling the iSpecimen team to respond to research inquiries with greater speed
Live Production Marketplace Now AvailableWoburn, Massachusetts--(Newsfile Corp. - February 6, 2026) - iSpecimen Inc. (NASDAQ:ISPC) today announced the successful completion of Milestone 2, System Integration and Marketplace Activation, marking a pivotal step in the SalesStack digital transformation journey. The milestone delivers a fully integrated, live marketplace that connects customer requests with supplier inventories, enabling streamlined operations, reduced costs, and a foundation for future growth.Chief Executive Officer Ms. Katie Field commented, "This Milestone 2 achievement demonstrates end-to-end system integration, legacy data migration, and activation of a production-ready Sale
Lexington, Massachusetts--(Newsfile Corp. - February 6, 2026) - iSpecimen Inc. (NASDAQ:ISPC), a leading provider of human biospecimens for research, is proud to announce recent milestones that demonstrate the strength, responsiveness, and reliability of its site network.Over the past several months, iSpecimen has been actively supporting customer research by sourcing high-quality respiratory samples, with a particular focus on influenza. Most recently, iSpecimen successfully collected 500 influenza swab samples in just a few weeks to support a customer research project—demonstrating its ability to respond quickly to time-sensitive research needs. The rapid turnaround and quality of the speci
3 - iSpecimen Inc. (0001558569) (Issuer)
3 - iSpecimen Inc. (0001558569) (Issuer)
3 - iSpecimen Inc. (0001558569) (Issuer)
8-K - iSpecimen Inc. (0001558569) (Filer)
DEFA14A - iSpecimen Inc. (0001558569) (Filer)
8-K - iSpecimen Inc. (0001558569) (Filer)
Craig-Hallum initiated coverage of iSpecimen with a rating of Buy and set a new price target of $20.00
EF Hutton reiterated coverage of iSpecimen with a rating of Buy and set a new price target of $12.00 from $10.00 previously
LEXINGTON, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that it appointed Eric Langlois as Chief Revenue Officer, effective immediately. Mr. Langlois previously served as the Company's Senior Vice President of Sales and Business Development. In this new role, Mr. Langlois will manage a restructured commercial team aimed at executing on Company initiatives to better align customer needs, streamline collaboration, support innovation and productivity necessary for driving sca
LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that its Board of Directors has appointed Tracy Curley, former Interim CEO, as CEO, effective immediately. "I am grateful to the Board and the entire team at iSpecimen for their support over the past four months, and for the confidence they have shown in my ability to lead the Company," said Tracy Curley, CEO of iSpecimen. "The progress we've made this year in terms of operational and financial execution is encouragi
LEXINGTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that the Company has appointed Joseph J. Basile to iSpecimen's Board of Directors (the "Board"), as well as the audit committee and the nominating and corporate governance committee of the Company, effective November 28, 2022. Mr. Basile is replacing Margaret H. Lawrence as an independent director. Mr. Basile is a sought-after strategic advisor, an accomplished business leader, a skilled negotiator, a trained mediato
SC 13G/A - iSpecimen Inc. (0001558569) (Subject)
SC 13D - iSpecimen Inc. (0001558569) (Subject)
SC 13G/A - iSpecimen Inc. (0001558569) (Subject)
Revenue increased 76% year-over-year to approximately $2.86 million Brielan Smiechowski Named SVP of Sales and Business Development LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and six month periods ended June 30, 2024. "iSpecimen's strong results reflect the progress we have made towards operational improvements throughout the Company this year, resulting in a 76% increase in revenue to $2.86 million for
LEXINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Tuesday, August 6, 2024. The Company will host a conference call and audio webcast that morning at 8:30 a.m. Eastern Time featuring remarks by Tracy Curley, CEO. Event:iSpecimen Second Quarter 2024 Results Conference Call Date:Tuesday, August 6, 2024 Time:8:30 a.m. Eastern Time Live Call:+1-800-717-1738
LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three-month period ended March 31, 2024. "iSpecimen made tremendous progress during the first quarter advancing our most promising operational initiative, Next Day Quotes, a program that expedites the biospecimen transaction process, which has helped elevate our market position and is expected to contribute meaningfully to our growth in 2024 and beyond," said Tracy Curley, C